Viz.ai and Avicenna.AI Partner to Launch World-class AI-Driven Intelligent Care Coordination for Pulmonary Embolism and Aortic Disease

Thursday, July 15, 2021

Viz.ai, the world leader in AI-driven intelligent care coordination, haspartnered with Avicenna.AI, a global leader in artificialintelligence solutions, to enable intelligent care coordination andimprove patient triage of patients suffering from pulmonary embolism (PE) andaortic disease. The collaboration will pave the way for faster clinicaldecision making and care for patients suffering from these two life threateningconditions.

Diagnosis and care coordination of patients sufferingfrom PE and aortic disease can be challenging. Avicenna.AI’s FDA-approved algorithms for PE andType A and Type B aortic dissection (AD),leveraged on the Vizintelligent care coordination platform, will empowermultidisciplinary care teams to easily coordinate patient care by sendingnotifications paired with dynamic imaging and detailed patient information toeach provider's desktop or mobile device as soon as a PE or an aorticdissection is detected. As part of Viz.ai’s commercial aortic module offering,access to imaging and workflows supporting the coordination of care forpatients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA),rupture, stenosis and transection will be available in addition to the ADalgorithm. Similarly, the PE algorithm will be available on Viz.ai’s commercialPE module.

“The addition of AI poweredworkflows should decrease the time from diagnosis to treatment and help tocoordinate care for patients suffering from life-threatening PE and aorticdisease, as it has in the treatment of ischemic stroke. It will help tofacilitate faster and easier treatment decisions across health systems, andthis should improve outcomes for patients,” said Dr. Richard Saxon,interventional radiologist Tri-City Medical Center.

The Viz Platform is proven tosave time and improve patient outcomes. In 2020, CMS granted Viz.ai a NewTechnology Add-on Payment (NTAP) for the stroke module, Viz LVO, whichreimburses hospitals directly. Pairing team alerts enhanced by AI withhigh-fidelity mobile image viewing, patient information and full-stack securecommunication enables multidisciplinary teams to make faster treatmentdecisions for patients. The result increases access to care and improvesoutcomes for patients.

"We are proud to become a trusted partner ofViz.ai, who is committed to giving access to high-standard healthcare systemsworldwide. Thanks to our AI-based solutions, we hope to facilitate an optimalmedical response within a short time frame and improve patient care. We lookforward to bringing the benefits of our pulmonary embolism and aorticdissection triage tools to the emergency room and beyond," said Cyril DiGrandi, chief executive officer of Avicenna.AI.

PE is a potentially deadly formof venous thromboembolic disease, a common cause of cardiovascular death, andis associated with multiple inherited and acquired risk factors affecting hundreds of thousands of people every year globally. PE occurs when a blood clot gets lodged in an artery inthe lung, blocking blood flow to part of the lung. Similar to PE, aorticdisease is potentially deadly and can require urgent surgical intervention toprevent death.

“We’re delighted to partner with Avicenna tobring intelligent care coordination to the peripheral vascular and vascularfields. This will form part of a broader Viz.AI platform, where any patientwith life threatening diseases can benefit from AI powered triage, fast mobilecommunication and synchronized care coordination,” said Dr. Chris Mansi, Viz.aiCEO and co-founder. “This partnership will bring the advantages of artificialintelligence to more patients and help hospitals achieve better clinicaloutcomes.”

About Avicenna.AI

Founded in 2018, Avicenna.AI develops medicalimaging AI solutions for various radiology applications. The company uses artificialintelligence and deep learning to optimize many of a radiologist's manualtasks. Its first product, CINA Head, is an FDA-approved triage AI solution forneurovascular emergencies. Avicenna.AI is co-founded by Cyril Di Grandi, whopreviously co-founded and successfully sold Olea Medical, and Dr Peter Chang, aradiologist and internationally recognized expert in AI and deep learning. www.avicenna.ai.

About Viz.ai, Inc.

Viz.ai is the leader inAI-driven intelligent care coordination. Viz.ai’s mission is to fundamentallyimprove how healthcare is delivered in the world, through intelligent softwarethat promises to reduce time to treatment, improve access to care, and increasethe speed of diffusion of medical innovation. Viz.ai’s clinically validatedplatform leverages advanced deep learning to communicate time-sensitiveinformation to specialists who can more quickly and easily make treatmentdecisions for the patient. In February 2018, the U.S. Food and DrugAdministration (FDA) granted a De Novo clearance for Viz LVO, the first-evercomputer-aided triage and notification software. Viz.ai announced its secondFDA clearance for Viz CTP through the 510(k) pathway, offering healthcareproviders an important tool for automated cerebral perfusion image analysis. Athird FDA clearance was granted in 2020 for Viz ICH, which uses AI toautomatically detect suspected intracranial hemorrhage on CT imaging. In 2020,CMS granted Viz.ai the first New Technology Add-on Payment (NTAP) forartificial intelligence software for Viz LVO.

Viz.ai is located in SanFrancisco and Tel Aviv and backed by leading Silicon Valley investors,including Kleiner Perkins, Google Ventures, Greenoaks, CRV, Threshold Ventures,Innovation Endeavors, Susa Ventures, Scale Venture Partners and InsightPartners.

MEDIA CONTACT:
Joe Duraes
Pazanga Health Communications
jduraes@pazangahealth.com
917-687-6419